Latest News
Wave Life Sciences, Inc.
- Wave Life Sciences will deliver third quarter earnings update: Can WVE break above $3.49?
- WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
- Wave Life Sciences announces virtual Research Day as stock rises 8%
- Wave Life Sciences at Chardan’s 10th Annual Healthcare Conference: chemistry focus
- H.C. Wainwright reiterates Buy on Wave Life Sciences stock By Investing.com
- Wave Life Sciences Aligns With FDA on Registrational Path for RNA Editing Therapy WVE-006 in AATD
- Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
- Wave Life Sciences reaches FDA alignment on WVE-006 trial design
- GSK selects Wave Life Sciences hepatology candidate
- GSK continues to stock up on Wave's RNA drugs with liver-focused program
- GSK Taps Wave Life Sciences’ siRNA Program, Triggering $12M Milestone Payment
- Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Headlines from the last 30 days, linking to the original publishers. See all market news →